PT  - JOURNAL ARTICLE
AU  - Nichols, Emma Hitt
TI  - HspB5 Improves MRI Lesions and Clinical Relapse in RRMS
DP  - 2014 Jul 01
TA  - MD Conference Express
PG  - 16--16
VI  - 14
IP  - 29
4099  - http://mdc.sagepub.com/content/14/29/16.short
4100  - http://mdc.sagepub.com/content/14/29/16.full
AB  - In patients with relapsing-remitting multiple sclerosis (RRMS), bimonthly injection with low-dose aB-crystallin (HspB5) resulted in a decrease in gadolinium-enhancing (Gd+) lesions and clinical relapses as compared with the placebo. This article presents data from a randomized study [2011-004475-36; van Noort JM et al. ACTRIMS/ECTRIMS 2014 (poster P082)] that evaluated HspB5 for the treatment of RRMS.